Evolving trends in lung cancer
Indian Journal of Cancer · 2022-03 · 59 (Suppl 1) · S90-S105
DOI: 10.4103/ijc.ijc_52_21 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Journal of Cancer, 2022-03. Verfasst von Ramakant Deshpand und 2 weiteren Autor:innen. Beteiligte Einrichtung: Consultant Surgical Oncologist, Asian Institute of Oncology, Mumbai, Maharashtra, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 99 Literaturangaben.
Abstract (Originalsprache)
Lung cancer is one of the deadliest cancers globally and accounts for most of the cancer-related deaths in India. Comprehensive data on lung cancer in India are lacking. This review aimed to discuss the epidemiological trends of lung cancers and driver mutations as well as the recent advancements in molecular diagnostics and therapeutic options primarily in non–small cell lung cancer (NSCLC) in India. Electronic databases, such as PubMed and Google Scholar, were searched to retrieve the relevant literature published in the past 5 years. As per the GLOBOCAN 2018 report, lung cancer was ranked the fourth leading cause of cancer (5.9% cases) in India, in all ages and sexes. Furthermore, 63,475 of all cancer-related deaths (8.1%) were attributed to lung cancer (cumulative risk 0.60), making it the third leading cause of cancer-related mortality. The common targets for treatment in lung cancer patients mainly include EGFR mutation, ALK and ROS1 rearrangements and PDL1 expression. In India, EGFR and ALK re-arrangement are commonly reported, but there is limited data of PD-L1 expression. Molecular testing has gained importance as several biomarkers are being targeted to treat lung cancer patients. Surgery, radiotherapy, systemic chemotherapy, and personalized molecular-targeted therapy prolong the overall survival (OS) in patients with NSCLC. Although chemotherapy and molecular-targeted therapies have greatly improved the clinical outcomes, prolonged disease control could not be attained in most NSCLC patients. In this situation, immunotherapy seems to be potentially beneficial to obtain long-lasting disease control with minimal adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Consultant Surgical Oncologist, Asian Institute of Oncology, Mumbai, Maharashtra, India.
- Consultant Radiation Oncologist, Jupiter Hospital, Thane, Maharashtra, India.
- Consultant Medical Oncologist, Manipal Hospital, Bengaluru, Karnataka, India, Indiaz.
Zitieren
APA
Deshpand, R., Chandra, M., & Rauthan, A. (2022). Evolving trends in lung cancer. Indian Journal of Cancer, 59(Suppl 1), S90-S105. https://doi.org/10.4103/ijc.ijc_52_21
Vancouver
Deshpand R, Chandra M, Rauthan A. Evolving trends in lung cancer. Indian Journal of Cancer. 2022;59(Suppl 1):S90-S105. doi:10.4103/ijc.ijc_52_21
BibTeX
@article{Deshpand2022,
author = {Deshpand, Ramakant and Chandra, Manish and Rauthan, Amit},
title = {Evolving trends in lung cancer},
journal = {Indian Journal of Cancer},
year = {2022},
volume = {59},
number = {Suppl 1},
pages = {S90--S105},
doi = {10.4103/ijc.ijc_52_21}
}
EUVIMED